Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy

Author(s): Cristy Phillips, Atoossa Fahimi, Devsmita Das, Fatemeh S. Mojabi, Ravikumar Ponnusamy, Ahmad Salehi

Journal Name: Current Alzheimer Research

Volume 13 , Issue 1 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Locus coeruleus (LC) neurons in the brainstem send extensive noradrenergic (NE)-ergic terminals to the majority of brain regions, particularly those involved in cognitive function. Both Alzheimer’s disease (AD) and Down syndrome (DS) are characterized by similar pathology including significant LC degeneration and dysfunction of the NE-ergic system. Extensive loss of NE-ergic terminals has been linked to alterations in brain regions vital for cognition, mood, and executive function. While the mechanisms by which NE-ergic abnormalities contribute to cognitive dysfunction are not fully understood, emergent evidence suggests that rescue of NE-ergic system can attenuate neuropathology and cognitive decline in both AD and DS. Therapeutic strategies to enhance NE neurotransmission have undergone limited testing. Among those deployed to date are NE reuptake inhibitors, presynaptic α-adrenergic receptor antagonists, NE prodrugs, and β-adrenergic agonists. Here we examine alterations in the NE-ergic system in AD and DS and suggest that NE-ergic system rescue is a plausible treatment strategy for targeting cognitive decline in both disorders.

Keywords: Adrenergic system, Alzheimer’s disease, β-Adrenergic, Monoaminergic systems, Down syndrome, Dementia, Locus coeruleus.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 07 December, 2015
Page: [68 - 83]
Pages: 16
DOI: 10.2174/1567205012666150921095924

Article Metrics

PDF: 108
HTML: 15
PRC: 1